A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.
Background: The objective of this review and meta-analysis is to investigate the efficacy of conbercept and ranibizumab, combined with or without laser photocoagulation, in patients with macular edema secondary to retinal vein occlusion (RVO-ME).Methods: Several databases have been used to identify...
| Published in: | Medicine Vol. 99; no. 21; pp. 1 - 11 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | research systematic review tables/charts Journal Article |
| Published: |
Lippincott Williams & Wilkins
5/22/2020
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144330994&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 144330994 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00257974 2S6 jtl: Medicine issn: 00257974 maglogo: N pubinfo: dt: 5/22/2020 vid: 99 iid: 21 pid: 433 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 144330994 144330994 NLM32481293 144330994 10.1097/MD.0000000000020222 NLM32481293 144330994 ppf: 1 ppct: 10 formats: tig: atl: A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion. aug: au: Weishai Liu Yanjie Li Rongxia Cao Zichao Bai Weiqin Liu Liu, Weishai Li, Yanjie Cao, Rongxia Bai, Zichao Liu, Weiqin affil: Department of Ophthalmology, The First hospital of Shanxi Medical University, Taiyuan City, China sug: subj: Retinal Vein Occlusion Complications Macular Degeneration Drug Therapy Macular Degeneration Therapy Injections Retrospective Design Recombinant Proteins Administration and Dosage Angiogenesis Inhibitors Administration and Dosage Human Macular Degeneration Recombinant Proteins Therapeutic Use Tomography, Optical Coherence Clinical Trials Visual Acuity Drug Effects Angiogenesis Inhibitors Adverse Effects Recombinant Proteins Adverse Effects Combined Modality Therapy Methods Angiogenesis Inhibitors Therapeutic Use Meta Analysis Systematic Review ab: Background: The objective of this review and meta-analysis is to investigate the efficacy of conbercept and ranibizumab, combined with or without laser photocoagulation, in patients with macular edema secondary to retinal vein occlusion (RVO-ME).Methods: Several databases have been used to identify relevant publications. After screening, a meta-analysis was conducted to compare conbercept and ranibizumab with the support of RevMan 5.3 (Cochrane Library Software, Oxford, UK).Results: In this study, 9 randomized controlled trials and 6 retrospective trials were included with a total of 1180 patients. No significant difference was found in best corrected visual acuity (BCVA) or central macular thickness (CMT) in the baseline parameters [BCVA (weighted mean difference (WMD): -0.01; 95% confidence interval CI: -0.03 to 0.01; P = .17), CMT (WMD: 20.14; 95% CI: -26.70 to 66.97; P = .40). No significant differences were found in the improvements of BCVA and adverse events (AEs) between the 2 groups after injection of loading dosage [the 1st month BCVA (WMD: -0.01; 95% CI: -0.04 to 0.02; P = .54),the 3rd month BCVA (WMD: -0.02; 95% CI: --0.05 to 0.01; P = .23), the 6th month BCVA (WMD: -0.02; 95% CI: -0.05 to 0.01; P = .27), AEs (odds ratio: 0.84; 95% CI: 0.38 to 1.84; P = .66)]. However, there were significant differences between conbercept and ranibizumab treatment in terms of CMT [1st month CMT (WMD: -11.70; 95% CI: -19.71 to -3.68; P < .01), 3rd month CMT (WMD: -10.08; 95% CI: -15.62 to -4.53; P < .01), 6th month CMT (WMD: -15.83; 95% CI: -22.88 to -8.78; P < .01)] and the number of injections (WMD, -0.36; 95% CI: -0.68 to -0.04; P = .03).Conclusion: The current pooled evidence suggested that both therapies of intravitreal conbercept and intravitreal ranibizumab with or without laser photocoagulation are effective in vision function in RVO-ME patients, and confirmed that conbercept has advantages over ranibizumab in terms of CMT and the number of injections for treating RVO-ME. In addition, conbercept has the statistically same visual gains and safety as ranibizumab in RVO-ME patients. Longer-term follow-up surveys on the safety and effectiveness of these 2 treatment regimens are required. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|